Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 12, 2021

Primary Completion Date

January 10, 2023

Study Completion Date

January 10, 2023

Conditions
Sars-CoV2Acute Respiratory Distress SyndromeCOVID-19
Interventions
BIOLOGICAL

Mesenchymal Stromal Cells

Patients will be given the cell product by intravenous injection (into the vein through an IV line). Dose:1 x 10\^8 MSCs.

OTHER

Supportive Care

Patients will receive supportive care per their treating physician

Trial Locations (1)

77030

Houston Methodist Hospital, Houston

All Listed Sponsors
collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

collaborator

The Methodist Hospital Research Institute

OTHER

lead

Baylor College of Medicine

OTHER

NCT04345601 - Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) | Biotech Hunter | Biotech Hunter